

Edited by
Gerhard F. Ecker and Peter Chiba


 WILEY-VCH

Transporters as Drug Carriers

Structure, Function, Substrates

Volume 44

Series Editors:
R. Mannhold,
H. Kubinyi,
G. Folkers



Transporters as Drug Carriers

Structure, Function, Substrates

Edited by

Gerhard Ecker and Peter Chiba



WILEY-VCH Verlag GmbH & Co. KGaA

沈阳药科大学图书馆



Y2007344

Series Editors

Prof. Dr. Raimund Mannhold

Molecular Drug Research Group
Heinrich-Heine-Universität
Universitätsstrasse 1
40225 Düsseldorf
Germany
mannhold@uni-duesseldorf.de

Prof. Dr. Hugo Kubinyi

Donnersbergstrasse 9
67256 Weisenheim am Sand
Germany
kubinyi@t-online.de

Prof. Dr. Gerd Folkers

Collegium Helveticum
STW/ETH Zurich
8092 Zurich
Switzerland
folkers@collegium.ethz.ch

Volume Editors

Prof. Dr. Gerhard Ecker

University of Vienna
Department of Medicinal Chemistry
Althanstrasse 14
1090 Wien
Austria
gerhard.f.ecker@univie.ac.at

Prof. Dr. Peter Chiba

Institut für Medizinische Chemie
Medizinische Universität Wien
Währinger Straße 10
1090 Wien
Austria
peter.chiba@meduniwien.at

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Cover Grafik-Design Schulz, Fußgönheim
Typesetting Thomson Digital, Noida, India
Printing and Binding Strauss GmbH, Mörlenbach

Printed in the Federal Republic of Germany
Printed on acid-free paper

ISBN: 978-3-527-31661-8

List of Contributors

Dana L. Abramovitz

Ingenuity Systems, Inc.
1700 Seaport Blvd., Third Floor
Redwood City, CA 94063
USA

Barbara Bennani-Baïti

University of Vienna
Pharmacy Center
Department of Medicinal Chemistry
Althanstraße 14
1090 Vienna
Austria

Keith Bostian

Mpex Pharmaceuticals, Inc.
11535 Sorrento Valley Road
San Diego, CA 92121
USA

Richard Callaghan

University of Oxford
John Radcliffe Hospital
Nuffield Department of Clinical
Laboratory Sciences
Oxford OX3 9DU
UK

Pedro Cano-Soldado

University of Barcelona (IBUB)
Department of Biochemistry and
Molecular Biology
Diagonal 645
08028 Barcelona
Spain
and
CIBER EHD
Barcelona
Spain

Francisco Javier Casado

University of Barcelona (IBUB)
Department of Biochemistry and
Molecular Biology
Diagonal 645
08028 Barcelona
Spain
and
CIBER EHD
Barcelona
Spain

Peter Chiba

Medical University of Vienna
Institute of Medical Chemistry
Währingerstrasse 10
1090 Vienna
Austria

Dirk R. de Waart

Academic Medical Center
AMC Liver Center
Meibergdreef 71
1105 BK Amsterdam
The Netherlands

Gerhard F. Ecker

University of Vienna
Department of Medicinal Chemistry
Althanstraße 14
1090 Wien
Austria

Sean Ekins

Collaborations in Chemistry
601 Runnymede Avenue
Jenkintown, PA 19046
USA

Robert C. Ford

University of Manchester
Faculty of Life Sciences
Manchester Interdisciplinary Biocentre
Manchester M1 7DN
UK

Gert Fricker

Institute of Pharmacy and Molecular
Biotechnology
Im Neuenheimer Feld 366
69120 Heidelberg
Germany

Walter Glaser

Medical University Vienna
Max F. Perutz Laboratories
Christian Doppler Laboratory for
Infection Biology
Dr. Bohr-Gasse 9/2
1030 Vienna
Austria

Klaus Gundertofte

H. Lundbeck A/S
Medicinal Chemistry Research
Ottiliavej 9
2500 Valby-Copenhagen
Denmark

Walter Jäger

University of Vienna
Department of Clinical Pharmacy and
Diagnostics
1090 Vienna
Austria

Alhaji B. Kamis

University of Manchester
Faculty of Life Sciences
Manchester Interdisciplinary Biocentre
Manchester M1 7DN
UK

Ian D. Kerr

University of Nottingham
Queen's Medical Centre
School of Biomedical Sciences
Centre for Biochemistry and Cell
Biology
Nottingham NG7 2UH
UK

Cornelia Klein

Medical University Vienna
Max F. Perutz Laboratories
Christian Doppler Laboratory for
Infection Biology
Dr. Bohr-Gasse 9/2
1030 Vienna
Austria

Meric Koksai

Yeditepe University
 Faculty of Pharmacy
 Department of Pharmaceutical
 Chemistry
 Kayisdagi, Kadikoy, Istanbul 34755
 Turkey

Karl Kuchler

Medical University Vienna
 Max F. Perutz Laboratories
 Christian Doppler Laboratory for
 Infection Biology
 Dr. Bohr-Gasse 9/2
 1030 Vienna
 Austria

Olga Lomovskaya

Mpex Pharmaceuticals, Inc.
 11535 Sorrento Valley Road
 San Diego, CA 92121
 USA

Míriam Molina-Arcas

University of Barcelona (IBUB)
 Department of Biochemistry and
 Molecular Biology
 Diagonal 645
 08028 Barcelona
 Spain

and

CIBER EHD
 Barcelona
 Spain

Winfried Neuhaus

Pharma Con GmbH
 Riglergasse 4/5
 1180 Vienna
 Austria

Christian R. Noe

University of Vienna
 Department of Medicinal Chemistry
 Althanstraße 14
 1090 Vienna
 Austria

Ronald P.J. Oude Elferink

Academic Medical Center
 AMC Liver Center
 Meibergdreef 71
 1105 BK Amsterdam
 The Netherlands

Maral Pastor-Anglada

University of Barcelona (IBUB)
 Department of Biochemistry and
 Molecular Biology
 Diagonal 645
 08028 Barcelona
 Spain

and

CIBER EHD
 Barcelona
 Spain

Tobias Schwarzmüller

Medical University Vienna
 Max F. Perutz Laboratories
 Christian Doppler Laboratory for
 Infection Biology
 Dr. Bohr-Gasse 9/2
 1030 Vienna
 Austria

Martin Valachovic

Medical University Vienna
 Max F. Perutz Laboratories
 Christian Doppler Laboratory for
 Infection Biology
 Dr. Bohr-Gasse 9/2
 1030 Vienna
 Austria

Mine Yarim

Yeditepe University
Faculty of Pharmacy
Department of Pharmaceutical
Chemistry
Kayisdagi, Kadikoy, Istanbul 34755
Turkey

Helen I. Zgurskaya

University of Oklahoma
Department of Chemistry and
Biochemistry
620 Parrington Oval, Room 208
Norman, OK 73019
USA

Preface

Although the phenomenon of multidrug resistance of bacteria was observed more than fifty years ago, it took 20 years until the first drug transporter, P-glycoprotein, was discovered as the responsible cellular factor for the outward transport of xenobiotics of different chemical structure. Another ten years later, experimental results on different tumor cell lines indicated that P-glycoprotein also occurs in advanced cancers and plays a major role in contributing to the non-response to chemotherapy.

The broad role of transporters in drug absorption, distribution and elimination, as well as in drug-drug interactions and (multi)drug resistance has only been recognized in recent decades. For almost a century it seemed clear that lipophilicity governs drug absorption and distribution. It was well accepted that drugs that mimic endogenous substrates, like amino acid, sugar and nucleoside analogs, use transporters to cross cell membranes but it was considered to be limited to such compound classes. However, in recent years more and more transporters were discovered and with this increasing number also more and more cases of active drug transport were observed. This fact even generated the speculation that in drug absorption active transport is rather the rule than the exception, another extreme hypothesis. A definite answer to this open question cannot be given at the very moment but it is interesting to watch the engaged discussion on the pros and cons.

In addition to their role in drug absorption, distribution and elimination, transporters are also responsible for certain drug-drug interactions. Drugs like verapamil, propafenone and quinidine are P-glycoprotein inhibitors; co-medication of these drugs with other active agents, normally eliminated by P-glycoprotein, may generate serious side effects. Non-sedating H₁ antihistaminics cross the blood-brain barrier like the classical, sedating antihistaminics but active efflux avoids their interaction with central histamine receptors. The opiate loperamide is a selective antidiarrhoic agent; however, if P-glycoprotein is inhibited by quinidine, loperamide exerts the typical central effects of all other opiates. Some drugs and even “harmless” agents, such as St. Johns Wort or grapefruit juice, induce the expression of drug-metabolizing cytochromes and of drug transporters, leading to other drug-drug interactions.

The book by Gerhard Ecker and Peter Chiba collects and evaluates the available evidence for further research in this hot area. For this purpose, the editors assembled a team of experienced scientists to discuss the important role of drug transporters in detail. We are very grateful to all authors for their excellent contributions, as well as to Frank Weinreich and Waltraud Wüst for their ongoing engagement for our series *Methods and Principles in Medicinal Chemistry*, in which this book will be another highlight.

April 2009

Raimund Mannhold, Düsseldorf
Hugo Kubinyi, Weisenheim am Sand
Gerd Folkers, Zurich

A Personal Foreword

An Introduction to the Medicinal Chemistry of Drug Transport

Membrane transporters are encoded by numerous gene families, comprising in total 883 genes encoding a broad variety of transporters. This so-called transportome performs important functions for the cell, such as providing nutrients, protecting the cell from xenotoxins, and establishing electrochemical gradients across membranes. Numerous disorders caused by mutations in transporter and channel genes underscore the physiological relevance of transport proteins. These include the Dubin–Johnson syndrome (ABCC2), sitosterolemia (ABCG5/G8), and Tangier disease (ABCA1), to mention a few. Membrane transporters also play a key role in ADME, affecting absorption, distribution, and elimination of drugs. Recently, this has also been recognized by regulatory authorities and the FDA published guidance for how to deal with transport processes. In addition, some ABC (ATP-binding cassette) transporters such as the multiple drug resistance transporter ABCB1 (P-glycoprotein) mediate energy-dependent efflux of drugs and thereby significantly contribute to the development of drug resistance. With respect to the latter, one should also note that numerous transporters have been identified in bacteria, fungi, and plasmodia and are responsible for resistance against chemotherapeutic agents in these organisms.

Given the large number of transport proteins and potential substrates, only a very small percentage of the possible pharmacological interactions among them have been studied so far. Those interactions may be particularly important in the chemotherapy of cancer, for drug–drug and drug–nutrient interactions, and for the bioavailability and brain permeation of drug candidates. Classical examples include the interaction of cyclosporin A with several statins and also the well-known multifactorial interaction of grape fruit juice: naringine is blocking OATP1A2, hesperidin is blocking ABCB1, and bergamottin is interacting with CYP3A4. This leads to a reduction in the plasma concentration of, for example, fexofenadine, talinolol, and celirolol. However, drug–drug interactions at transport proteins might also be used in a beneficial way. During the Second World War, the so-called wartime tactic was applied by coadministering penicillin with probenecid. Blocking of hOAT

transporters in the kidney by probenecid enabled a significant reduction in the penicillin dosing and thus treatment of a higher number of patients. An identical approach has recently been proposed for tamiflu.

Nonetheless, a systematic study of the transportome's role in ADE (absorption, distribution, and elimination), chemosensitivity, and chemoresistance is still lacking. Furthermore, from a systems point of view, the situation is even more complex. Nuclear receptors, cytochromes, and transporters form a protein network responsible for elimination and toxification/detoxification of most of the drugs currently used. This network is subject to multifactorial influences, such as induction of the expression of P-glycoprotein by St. John's wort. Last but not the least, there is increasing evidence of considerable species-specific differences. Thus, using quantitative proteomics could demonstrate that in humans the amount of ABCG2 at the blood–brain barrier is twofold the amount of ABCB1, whereas in rodents the ratio is almost 1: 1. Another example is the CNS toxicity of ivermectin in collie dogs, which lack functional P-glycoprotein at the blood–brain barrier due to an MDR1-1delta mutation.

This volume of *Methods and Principles in Medicinal Chemistry* features different classes of membrane transport proteins and highlights their importance in the field of medicinal chemistry. Part One highlights the importance of several human transporter families as drug carriers. Special focus is given on the structure and function of P-glycoprotein, the paradigm protein in the field. The recently published X-ray structure of mouse P-gp now also paves the way for structure-guided modeling studies. The chapter on CNS transporters has been kept short as these will be covered in an upcoming volume of this series. Part Two focuses on drug transporters in bacteria and fungi, which are relevant for medicinal chemists. Part Three gives an overview on rational drug design approaches pursued for prediction of interaction of transporters with their ligands. Part Four is devoted to the role of drug transporters at physiological barriers as well as the interplay of transporters and metabolic enzymes. Finally, an overview on systems biology approaches and the role of drug transporters under pathophysiological conditions is given.

We were in the favorite position to win a number of high-profile research scientists to contribute to this effort and share their views and opinions. We would like to thank all authors for their excellent contributions and also for their patience during the editing process. We would also like to express our sincere appreciation to Frank Weinreich, Waltraud Wüst, and the helpful hands at Wiley-VCH for their excellent support in the production of this book. Finally, we also thank Raimund Mannhold, Hugo Kubinyi, and Gerd Folkers for their enthusiasm and continuous efforts to provide the medicinal chemistry community with this outstanding *Methods and Principles* series of books.

Enjoy reading!

Vienna, Summer 2009

Peter Chiba and Gerhard Ecker

Contents

List of Contributors	XIII
Preface	XVII
A Personal Foreword	XIX

Part One: Human Transporter Families – Structure, Function, Physiology 1

1	The ABC Transporters: Structural Insights into Drug Transport 3
	<i>Robert C. Ford, Alhaji B. Kamis, Ian D. Kerr, and Richard Callaghan</i>
1.1	ABC Proteins – Structure and Function 3
1.1.1	ABC Proteins 3
1.1.2	Predicted Topology of ABC Proteins 4
1.1.3	Nucleotide Binding Domains 4
1.1.3.1	Conserved Motifs of NBDs 5
1.1.4	Transmembrane Domains 5
1.1.5	Mechanisms of Transport 5
1.1.6	Energy for Translocation 6
1.1.7	Coupling of ATP Hydrolysis to Transport 7
1.2	Structures of ABC Transporters 7
1.2.1	Tertiary Structure 7
1.2.2	Quaternary Structure of ABC Proteins 11
1.3	Multidrug Resistance and ABC Transporters 15
1.3.1	P-Glycoprotein 15
1.3.1.1	Historical Background 15
1.3.1.2	The Role of P-gp in Drug Resistance 16
1.3.1.3	Tissue Distribution and Physiological Roles 17
1.3.2	Conformational Changes in the Mechanism of P-gp 17
1.3.3	Comparison of Sav1866 and P-gp Structures 19
1.3.4	Drug Binding Sites in P-Glycoprotein 21
1.3.5	Structural Interpretation of Drug Binding 25
1.3.6	Inhibitors of P-gp 27
1.3.7	What Properties Are Shared by Drugs that Interact with P-Glycoprotein? 29

1.3.8	Postscript: Further X-ray Crystallographic Studies and a Structure for the Nucleotide-Free State of P-Glycoprotein	30
1.4	Summary	31
	References	31

2 Biochemistry, Physiology, and Pharmacology of Nucleoside and Nucleobase Transporters 49

Marçal Pastor-Anglada, Míriam Molina-Arcas, Pedro Cano-Soldado, and Francisco Javier Casado

2.1	Nucleoside and Nucleobase Transporters	49
2.1.1	Equilibrative Nucleoside Transporters	50
2.1.2	Concentrative Nucleoside Transporters	51
2.2	ENT and CNT Tissue Distribution, Regulation, and Physiological Roles	53
2.2.1	ENT Tissue Distribution and Regulation	54
2.2.2	CNT Tissue Distribution and Regulation	56
2.2.2.1	CNTs in Absorptive Epithelia	57
2.2.2.2	CNTs in Liver Parenchymal Cells	57
2.2.2.3	CNTs in Immune System Cells	58
2.2.2.4	CNTs in CNS	59
2.2.2.5	CNTs in Other Specialized Tissues	60
2.2.3	NTs as “Transceptors”	60
2.3	Nucleoside- and Nucleobase-Derived Drug Transport into Cells	61
2.3.1	Transport of Anticancer Drugs	61
2.3.2	Transport of Antiviral Drugs	63
2.4	Drug Transport and Responsiveness to Treatment	65
2.4.1	Analysis of the Role of NTs in Sensitivity to Nucleoside Anticancer Drugs in Cultured Cell Models	65
2.4.2	Studies Linking NT Function to Drug Sensitivity and Clinical Outcome in Cancer Patients	67
2.5	Future Perspectives	69
	References	70

3 Organic Anion Transporting Polypeptides (Oatps/OATPs) 81

Mine Yarim and Meric Koksal

3.1	Introduction	82
3.2	Nomenclature and Classification	82
3.3	Tissue Distribution, Structure, and Functions	83
3.4	Substrate Spectrum	85
3.5	Members of the Rodent Oatp Family	93
3.5.1	Oatp1a1	93
3.5.2	Oatp1a3-v1/v2	93
3.5.3	Oatp1a4	93
3.5.4	Oatp1a5	94
3.5.5	Oatp1a6	94

3.5.6	Oatp1b2	94
3.5.7	Oatp1c1	95
3.5.8	Oatp2a1	95
3.5.9	Oatp2b1	95
3.5.10	Oatp3a1	95
3.5.11	Oatp4a1	96
3.5.12	Oatp4c1	96
3.5.13	Oatp6b1/Oatp6c1	96
3.5.14	PGT-2	96
3.5.15	TST-1 and TST-2	97
3.6	Members of Nonmammalian Oatp Family	97
3.7	Members of Human OATP Family	97
3.7.1	OATP1A2	97
3.7.2	OATP1B1	98
3.7.3	OATP1B3	98
3.7.4	OATP1C1	99
3.7.5	OATP2A1	99
3.7.6	OATP2B1	99
3.7.7	OATP3A1	100
3.7.8	OATP4A1	100
3.7.9	OATP4C1	100
3.7.10	OATP5A1	100
3.7.11	OATP6A1	100
3.8	Drug Disposition and Drug–Drug Interactions	101
3.9	Computational Approaches	102
3.10	Conclusions	103
	References	104

4 CNS-Transporters as Drug Targets 113

Klaus Gundertofte

4.1	Introduction	113
4.2	Structure of Transporters	113
4.3	Monoamine Transporters	114
4.4	Transporters for Amino Acids	115
4.5	Nonneurotransmitter Transporters	116
4.6	Concluding Remarks	116
	References	117

Part Two: Drug Transport in Microorganisms and Fungi 119

5 Bacterial Multidrug Transporters: Molecular and Clinical Aspects 121

Olga Lomovskaya, Helen I. Zgurskaya, and Keith Bostian

5.1	Introduction	121
5.1.1	The Multiple Antibiotic Resistance Problem	121

5.1.2	The Superbugs	121
5.1.3	The Multidrug Resistance Transporters	122
5.2	Diversity of Bacterial MDR Efflux Systems	123
5.2.1	ABC Transporters	124
5.2.2	MFS Transporters	126
5.2.3	MATE MDR Transporters	127
5.2.4	SMR MDR Transporters	128
5.2.5	RND MDR Transporters	129
5.2.6	Diversity on a Theme	133
5.3	Accessory Proteins from Gram-Negative Bacteria	134
5.4	Efflux and Antibiotic Resistance	136
5.4.1	Gram-Positive Efflux Resistance	137
5.4.2	Gram-Negative Efflux Resistance	139
5.4.3	Inhibiting Gram-Negative RND Pumps	141
5.5	The Search for Efflux Inhibitors	143
5.6	Challenges and Perspectives	144
	References	146
6	Membrane Transporters in Pleiotropic Drug Resistance and Stress Response in Yeast and Fungal Pathogens	159
	<i>Tobias Schwarzmüller, Cornelia Klein, Martin Valachovic, Walter Glaser, and Karl Kuchler</i>	
6.1	Introduction	159
6.2	ABC Protein Genes in <i>S. cerevisiae</i>	162
6.2.1	The PDR Family	163
6.2.2	The MRP/CFTR Family	167
6.3	Orchestrating Pleiotropic Drug Resistance: The PDR Network	168
6.4	ABC Drug Transporters of Human Fungal Pathogens	171
6.5	Physiological Roles of Drug Transporting ABC Proteins – Search for Substrates	176
6.6	Conclusions and Perspectives	177
	References	178

Part Three: Structure Activity Relationship Studies on ABC Transporter 195

7	QSAR Studies on ABC Transporter – How to Deal with Polyspecificity	197
	<i>Gerhard F. Ecker</i>	
7.1	The Problem of Polyspecificity/Promiscuity	197
7.2	QSAR Approaches to Design Inhibitors of P-glycoprotein (ABCB1)	197
7.3	Other ABC Transporter	206
7.3.1	ABCG2 (Breast Cancer Resistance Protein, MXR)	206
7.3.2	ABCC1 and ABCC2 (Multidrug Resistance-Related Proteins 1 and 2)	207

- 7.3.3 ABCB11 (Bile Salt Export Pump) 208
- 7.4 Novel Methods 209
- 7.5 Structural Basis for Polyspecificity 210
- 7.6 Conclusions and Outlook 210
- References 211

8 Drug Transporter Pharmacophores 215

Sean Ekins

- 8.1 Introduction 215
- 8.2 Database Searching with Transporter Pharmacophores 217
- 8.3 Summary 220
- References 221

Part Four: Transporters and ADME 229

9 Biological Membranes and Drug Transport 231

Gert Fricker

- 9.1 Biological Membranes 231
 - 9.1.1 Lipid Bilayer 231
 - 9.1.2 Membrane Proteins 233
 - 9.1.3 Membrane Carbohydrates 233
- 9.2 Membrane Transport 233
 - 9.2.1 Mechanisms of Transport 233
 - 9.2.2 Transport Across Lipid Membranes 233
 - 9.2.3 Protein-Coupled Membrane Transport 235
 - 9.2.4 Kinetics of Carrier-Mediated Transport Processes 236
 - 9.2.5 Ion Gradient-Dependent Transport Processes 237
 - 9.2.6 Cytotic Mechanisms: Transport of Macromolecules 238
 - 9.2.7 Export Proteins 238
- 9.3 Pharmacokinetic-Relevant Membrane Barriers 239
 - 9.3.1 Intestinal Drug Absorption 239
 - 9.3.2 Liver 244
 - 9.3.3 Kidney 246
 - 9.3.4 Blood–Brain Barrier and Choroid Plexus 251
- References 254

10 Transport at the Blood–Brain Barrier 263

Winfried Neuhaus and Christian R. Noe

- 10.1 The Blood–Brain Barrier 263
- 10.2 Transport Mechanisms Across the Blood–Brain Barrier 267
- 10.3 The Physical Barrier: Paracellular Transport and Its Characterization 270
- 10.4 The Efflux Barrier: Transport Proteins at the Blood–Brain Barrier 272
- 10.5 Transporter of the SLC Transporter Family 274

10.5.1	Monocarboxylate Transporters	274
10.5.2	Organic Ion Transporters and Transporting Peptides	276
10.6	Transporter of the ABC Transporter Family	278
10.6.1	P-Glycoprotein	278
10.6.2	Multidrug Resistance-Associated Proteins	282
10.6.3	Breast Cancer Resistance Protein	284
10.7	The Metabolic Barrier: Enzymes at the Blood–Brain Barrier	285
10.8	How to Overcome the Blood–Brain Barrier	286
	References	286
11	Bile Canalicular Transporters	299
	<i>Dirk R. de Waart and Ronald P.J. Oude Elferink</i>	
11.1	Introduction	300
11.2	ABCC2	301
11.3	ABCG2	304
11.4	ABCB1	305
11.5	ABCB4	306
11.6	ABCB11	307
11.7	ABCG5 and ABCG8	308
11.8	Canalicular Transporters as Targets for Drug Delivery	309
	References	313
12	Interplay of Drug Metabolizing Enzymes and ABC Transporter	325
	<i>Walter Jäger</i>	
12.1	Combined Role of Cytochrome P450 3A and ABCB1	325
12.2	Combined Role of Cytochrome P450 3A and OATPs	329
12.3	Combined Role of UDP-Glucuronosyltransferases and ABCC2	332
12.4	Biopharmaceutical Classification System	337
	References	342
13	ABC Transporters – From Targets to Antitargets?	349
	<i>Gerhard F. Ecker and Peter Chiba</i>	
13.1	Introduction	349
13.2	ABC Transporters as Targets	349
13.2.1	P-Glycoprotein (ABCB1)	350
13.2.2	Other ABC Transporter as Drug Targets	353
13.2.2.1	ABCG2 (Breast Cancer Resistance Protein, MXR)	353
13.2.2.2	ABCC1 and ABCC2 (Multidrug Resistance Proteins 1 and 2)	353
13.3	P-Glycoprotein – An Antitarget?	354
13.3.1	Gastrointestinal Absorption	354
13.3.2	Brain Uptake	355
13.4	Predicting Substrate Properties for P-Glycoprotein	355
13.4.1	Data Sets	356
13.4.2	Classification Models	356
13.4.3	Pharmacophore Models	358